Trump Administration Proposes Medicare Drug Pricing Reform
The Trump administration has put forward a proposal aimed at stopping hospitals from marking up discounted drugs for Medicare patients, with estimated savings of $1.1 billion in the coming year, according to reports from the Associated Press. The proposed regulations carefully target hospitals participating in the 340B program, which allows the purchase of outpatient drugs at reduced prices, thereby addressing cost efficiency in healthcare.
The Centers for Medicare & Medicaid Services (CMS) is driving this initiative to adjust the 340B program's reimbursement formula. This strategic move seeks to lower expenses for patients, thereby enhancing healthcare affordability—a critical concern for both households and governmental budgets. The administration's focus on economic efficiency marks an important step in healthcare reform.
However, the American Hospital Association has raised concerns about the financial impact these regulations might have on healthcare providers. According to Ashley Thompson, the association's senior vice president, the proposed changes could potentially hinder hospitals' ability to deliver vital services and maintain accessible care for low-income patients, emphasizing the delicate balance between regulatory compliance and service delivery.
Potential revenue implications for hospitals are at stake, possibly affecting local community services. The 340B program was initially designed to expand federal resources, allowing providers to reach more patients. However, it has become a point of contention between healthcare providers and pharmaceutical firms, reflecting broader industry challenges.
The CMS estimates suggest a significant reduction in costs for Medicare Part B beneficiaries, with co-payment reductions of approximately $800 annually, leading to an aggregate national saving of $1.1 billion. Over the span of a decade, the potential cumulative savings could soar to approximately $20 billion, demonstrating substantial fiscal impacts.
A specific case involving Lupron Depot, a prostate cancer drug, highlights the issue: While hospitals purchase it for about $700, Medicare reimbursement approaches $4,000 with an additional $1,000 from patient co-payments. The new proposal would aim to cut this reimbursement by 40%, aligning payment structures with market realities.
In 2018, a similar rule proposed during Trump's first term faced challenges when the Supreme Court ruled against separate reimbursement systems for 340B hospitals. The new proposal, following an executive order in April 2025, suggests capping Medicare reimbursement at the average sales price minus 33.4%, set to take effect early next year if approved.